Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Titan Pharmaceuticals Inc. - news published 107 - readings 2.699

BACK

Titan Pharmaceuticals Inc.

Material Agreement (Form 8-K)

Item 1.01. Entry into a Material Definitive Agreement. Private Placement and Purchase Agreement On March 29, 2025, Titan Pharmaceuticals, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Blue Harbour Asset Management L.L.C-FZ (the "Investor"), pursuant to which the Company has agreed to issue 100,00 ...

01.04.2025

Titan Pharmaceuticals Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

Management's Discussion and Analysis of Financial Condition and Results of Operations. Overview Titan is a pharmaceutical company incorporated as a Delaware corporation in 1992. Prior to the sale of assets that occurred in September 2023 (as described below), we focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura ® , for the ...

20.03.2025

Titan Pharmaceuticals Inc.

Failure to Satisfy Listing Rule Form 8 K

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 3, 2025, Titan Pharmaceuticals, Inc. (the "Company") received a notice (the "Notice") from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market ("Nasdaq") that the Company is in noncompliance with Listing Rules ...

08.01.2025

Titan Pharmaceuticals Inc.

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 . OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to __________ ...

03.01.2025

Titan Pharmaceuticals Inc.

Management Change/Compensation Form 8 K

Item 4.01. Change in Registrant's Certifying Accountant. The Audit Committee of Titan Pharmaceuticals, Inc. (the "Company") recently completed a selection process to determine the Company's independent registered public accounting firm. As a result of this process, the Audit Committee approved the appointment of Enrome LLP ("Enrome") as the Company's indepe ...

06.12.2024

Titan Pharmaceuticals Inc.

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

Press Releases Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq Download as PDF November 27, 2024 NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock ...

27.11.2024

Titan Pharmaceuticals Inc.

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq Form 8 K

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq NEW YORK, NY, November 27, 2024 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the ...

27.11.2024

Titan Pharmaceuticals Inc.

Late Filing Notice Form NT 10 Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION SEC FILE NUMBER Washington, D.C. 20549 001-13341 FORM 12b-25 CUSIP NUMBER 888314705 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☑ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 Nothing in this form shall be construed to imply that the Commission ...

15.11.2024

Titan Pharmaceuticals Inc.

Management Change/Compensation Form 8 K

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, Compensatory Arrangements of Certain Officers. On November 6, 2024, the Board of Directors of Titan Pharmaceuticals, Inc. (the "Company") appointed Brynner Chiam, a director of the Company, as acting principal executive officer and acting principal financial ...

08.11.2024

Titan Pharmaceuticals Inc.

Management Change/Compensation Form 8 K

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, Compensatory Arrangements of Certain Officers. On October 24, 2024, Dato' Seow Gim Shen notified the Board of Directors of Titan Pharmaceuticals, Inc. (the "Company") of his decision to resign as Chief Executive Officer and Chairman of the Board of the Compa ...

24.10.2024

Titan Pharmaceuticals Inc.

TITAN PHARMACEUTICALS ENTERS INTO MERGER AGREEMENT WITH KE SDN. BHD Form 8 K

TITAN PHARMACEUTICALS ENTERS INTO MERGER AGREEMENT WITH KE SDN. BHD. NEW YORK, NY, August 19, 2024 /GLOBE NEWSWIRE/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan") today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the "Merger Agreement") regarding a business combination with KE Sdn. Bhd. ("KE" ...

19.08.2024

Titan Pharmaceuticals Inc.

Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

Press Releases Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. Download as PDF August 19, 2024 NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan") today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the "Merger Agreement") regarding a business comb ...

19.08.2024

Titan Pharmaceuticals Inc.

Late Filing Notice Form NT 10 Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION SEC FILE NUMBER Washington, D.C. 20549 001-13341 FORM 12b-25 CUSIP NUMBER 888314705 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☑ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 Nothing in this form shall be construed to imply that the Commission has ...

15.08.2024

Titan Pharmaceuticals Inc.

Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 . OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Co ...

15.08.2024

Titan Pharmaceuticals Inc.

Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 . OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ C ...

15.05.2024

Titan Pharmaceuticals Inc. - news published 107 - readings 2.699

Titan Pharmaceuticals Inc.

Material Agreement (Form 8-K)

Titan Pharmaceuticals Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

Titan Pharmaceuticals Inc.

Failure to Satisfy Listing Rule Form 8 K

Titan Pharmaceuticals Inc.

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

Titan Pharmaceuticals Inc.

Management Change/Compensation Form 8 K

Titan Pharmaceuticals Inc.

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

Titan Pharmaceuticals Inc.

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq Form 8 K

Titan Pharmaceuticals Inc.

Late Filing Notice Form NT 10 Q

Titan Pharmaceuticals Inc.

Management Change/Compensation Form 8 K

Titan Pharmaceuticals Inc.

Management Change/Compensation Form 8 K

Titan Pharmaceuticals Inc.

TITAN PHARMACEUTICALS ENTERS INTO MERGER AGREEMENT WITH KE SDN. BHD Form 8 K

Titan Pharmaceuticals Inc.

Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

Titan Pharmaceuticals Inc.

Late Filing Notice Form NT 10 Q

Titan Pharmaceuticals Inc.

Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)

Titan Pharmaceuticals Inc.

Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member